ArticleImmunity, inflammation and disease2026
Epidemiological Trends and Multidrug-Resistant Patterns in Central Line-Associated Bloodstream Infections Among Bone Marrow Transplant Patients at Comprehensive Cancer Center in Jordan: Five-Year Retrospective Study.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveCentral Line-Associated Bloodstream Infections (CLABSIs) considered a significant challenge in healthcare settings, necessitating vigilant monitoring and intervention strategies especially among patients undergoing Hematopoietic Stem Cell Transplantation (HSCT). This study aims to conduct comprehensive analysis of CLABSI cases among HSCT patients; trends in incidence, device associations, causative organisms, and multidrug-resistant patterns. METHODOLOGY: A retrospective analysis was conducted on HSCT patients who developed CLABSI at the King Hussein Cancer Center between January 2019 and December 2023. Data collected included demographic data (age and sex), Diagnosis, type of vascular access device (VAD), Organism, bacterial resistance pattern, and last follow-up status and date were collected for patients. Overall survival analysis was performed using the Kaplan-Meier method, with results reported at 30, 60, and 100 days post-infection.
resultsOver the 5-year period, 169 HSCT patients had CLABSI were included, the majority were male (65.7%), with 73% adults and 27% pediatric patients, and a mean age of 33.6 years. The most common diagnoses were lymphoma (25.4%) and leukemias (24.9%). Gram-negative bacteria were the predominant cause of infection, accounting for 85% of cases, followed by Gram-positive bacteria (13.0%) and fungi (2.4%). Escherichia coli was the most frequent causative organism (46%), followed by Klebsiella pneumoniae (8%) and Pseudomonas aeruginosa (5%). Multidrug-resistant pathogens, particularly Extended-Spectrum Beta-Lactamase (ESBL) producing strains and Carbapenem-resistant Enterobacteriaceae (CRE), were prevalent. Hickman devices were associated with the highest number of CLABSI cases (63.9%). The overall survival rates were 83.4% at 30 days, 80.5% at 60 days, and 78.1% at 100 days post-CLABSI.
conclusionThis study provides a comprehensive overview of CLABSI epidemiology among HSCT patients in Jordan, highlighting the high prevalence of Gram-negative and multidrug-resistant organisms. These findings underscore the critical need for continuous surveillance, targeted infection control measures, and effective antimicrobial stewardship to improve patient safety and outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.